Efficacy of anticoagulation therapy in end-stage renal disease patients with antiphospholipid antibody syndrome

Transplantation

Volumn 77, Issue 7, 2004, Pages 1046-1049

  Vaidya, Smita ^a,b   Gugliuzza, Kristine ^a   Daller, John A ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; WARFARIN;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DIALYSIS; DRUG EFFICACY; FEMALE; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHOSPHOLIPID ANTIBODY SYNDROME; PRIORITY JOURNAL; THROMBOSIS;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTHROMBIN TIME;

EID: 1942420159     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000119157.81765.46     Document Type: Article

References (10)

1. Vaidya S, Wang CC, Gugliuzza K, et al. Relative risk of post transplant renal thrombosis in patients with antiphospholipid antibodies. Clin Transplant 1998; 12: 439.
2. Vaidya S, Wang C, Gugliuzza K, et al. Antiphospholipid antibody syndrome and post-transplant renal thrombosis. Transpl Proc 1999; 31: 230.
3. Vaidya S, Sellers R, Kimball P, et al. Frequency potential risk and therapeutic intervention in end-stage renal disease patients with antiphospholipid antibody syndrome. Transplantation 2000; 69(7): 1348.
4. Khamasta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the anti-phospholipid antibody syndrome. N Engl J Med 1995; 332: 993.
5. Ruiz-Irastorza G, Khamasta MA, Hunt BJ, et al. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162(10): 1164.
6. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 11: 60.
7. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Potentiation of vitamin K antagonist by high dose of intravenous methylprednisolone. Ann Intern Med 2000; 132: 631.
8. Derkersen RH, de Groot PG, Kater L, et al. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 1993; 52: 689.
9. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303.
10. Joseph RE, Radhakrishnan J, Appel GB. Antiphospholipid antibody syndrome and renal disease. Curr Opin Nephrol Hyperten 2001; 10: 175.